Name
MacoMed OÜ
Registry code
16517455
VAT number
EE102504695
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
10.06.2022 (3)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
46181 - Agents specialised in the sale of other particular products
4 159 240 €
561 267 €
13%
2 932 €
(estimate is approximate)
676 659 €
6
Submitted
No tax arrears
83%
44%
| Owner | Representative | Beneficial owner | |
|---|---|---|---|
| Hendrik Pindmaa
| 100% - 2 500.00 EUR | Board member | Direct ownership |
| 2022 21.07.2023 | 2023 17.06.2024 | 2024 14.11.2025 | |
|---|---|---|---|
| Total Revenue | 1 319 449 € | 2 818 142 € | 4 159 240 € |
| Net profit (loss) for the period | 106 603 € | 133 879 € | 561 267 € |
| Profit Margin | 8% | 5% | 13% |
| Current Assets | 703 640 € | 346 412 € | 1 042 440 € |
| Fixed Assets | 74 470 € | 129 290 € | 245 129 € |
| Total Assets | 778 110 € | 475 702 € | 1 287 569 € |
| Current Liabilities | 671 507 € | 222 272 € | 578 531 € |
| Non Current Liabilities | - | 39 245 € | 32 379 € |
| Total Liabilities | - | 261 517 € | 610 910 € |
| Share Capital | - | - | - |
| Equity | 106 603 € | 214 185 € | 676 659 € |
| Employees | 4 | 4 | 6 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2025 Q4 | 919 400 € | 117 053 € | 41 227 € | 8 |
| 2025 Q3 | 1 480 399 € | 191 999 € | 40 287 € | 8 |
| 2025 Q2 | 1 012 722 € | 96 786 € | 39 326 € | 8 |
| 2025 Q1 | 1 567 613 € | 199 820 € | 31 981 € | 8 |
| 2024 Q4 | 1 606 689 € | 209 675 € | 31 341 € | 6 |
| 2024 Q3 | 1 110 480 € | 79 903 € | 26 780 € | 6 |
| 2024 Q2 | 2 095 939 € | 195 573 € | 23 654 € | 6 |
| 2024 Q1 | 938 940 € | 101 258 € | 21 041 € | 5 |
| 2023 Q4 | 1 100 249 € | 147 722 € | 17 245 € | 6 |
| 2023 Q3 | 787 491 € | 62 216 € | 15 439 € | 6 |
| 2023 Q2 | 1 556 547 € | 123 441 € | 15 509 € | 5 |
| 2023 Q1 | 1 431 617 € | 176 621 € | 13 455 € | 4 |
| 2022 Q4 | 923 989 € | 38 853 € | 5 738 € | 4 |
| 2022 Q3 | 168 496 € | 14 332 € | 0 € | 4 |
| 2022 Q2 | - | - | - | - |
| 2022 Q1 | - | - | - | - |
